The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
Open accessAbstract
Summary Ponatinib is the only currently approved tyrosine kinase inhibitor (TKI) that suppresses all BCR-ABL1 single mutants in Philadelphia chromosome-positive (Ph+) leukemia, including the recalcitrant BCR-ABL1T315I mutant. However, emergence of compound mutations in a BCR-ABL1 allele may confer ponatinib resistance. We found that clinically reported BCR-ABL1 compound mutants center on 12 key positions and confer varying resistance to imatinib, nilotinib, dasatinib, ponatinib, rebastinib and bosutinib. T315I-inclusive compound mutants confer high-level resistance to TKIs, including ponatinib. In vitro resistance profiling was predictive of treatment outcomes in Ph+ leukemia patients. Structural explanations for compound mutation-based resistance were obtained through molecular dynamics simulations. Our findings demonstrate that BCR-ABL1 compound mutants confer different levels of TKI resistance, necessitating rational treatment selection to optimize clinical outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Self-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Self-citationCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055104 · Cited by 1,344
Self-citationO'Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.028 · Cited by 1,259
Self-citationA Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306494 · Cited by 1,142
Self-citationMolecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Hochhaus, A., Kreil, S., Corbin, A., La Rosée, P., Müller, M., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N., Berger, U., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402741 · Cited by 906
Self-citationPonatinib in Refractory Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kantarjian, H., Shah, N. P., Bixby, D., Mauro, M. J., Flinn, I., O'Hare, T., Hu, S., Narasimhan, N. I., Rivera, V. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205127 · Cited by 769
Self-citation
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Response and Resistance to BCR-ABL1-Targeted Therapies
Braun, T. P., Eide, C. A., & Druker, B. J. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.006 · Cited by 483
Self-citationMartinelli, G., Boissel, N., Chevallier, P., Ottmann, O., Gökbuget, N., Topp, M. S., Fielding, A. K., Rambaldi, A., Ritchie, E. K., Papayannidis, C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.3531 · Cited by 445
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
Rossari, F., Minutolo, F., & Orciuolo, E. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0624-2 · Cited by 371
Yoda, S., Lin, J. J., Lawrence, M. S., Burke, B. J., Friboulet, L., Langenbucher, A., Dardaei, L., Prutisto-Chang, K., Dagogo-Jack, I., Timofeevski, S., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1256 · Cited by 322
A comprehensive review of protein kinase inhibitors for cancer therapy
Kannaiyan, R., & Mahadevan, D. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1527688 · Cited by 302
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Deininger, M. W., Shah, N. P., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., DeAngelo, D. J., Gotlib, J., Hobbs, G., Maness, L., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0047 · Cited by 262
Self-citationEide, C. A., Zabriskie, M. S., Savage Stevens, S. L., Antelope, O., Vellore, N. A., Than, H., Schultz, A. R., Clair, P., Bowler, A. D., Pomicter, A. D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.004 · Cited by 247
Self-citationAxitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation
Pemovska, T., Johnson, E., Kontro, M., Repasky, G. A., Chen, J., Wells, P., Cronin, C. N., McTigue, M., Kallioniemi, O., Porkka, K., et al. (2015) · Nature · doi:10.1038/nature14119 · Cited by 234
Alves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B. (2021) · Cancers · doi:10.3390/cancers13194820 · Cited by 204
Kim, T., Tyndel, M. S., Kim, H. J., Ahn, J.-S., Choi, S. H., Park, H. J., Kim, Y.-K., Kim, S. Y., Lipton, J. H., Zhang, Z., et al. (2017) · Blood · doi:10.1182/blood-2016-04-708560 · Cited by 133
Self-citationCross, N. C. P., Ernst, T., Branford, S., Cayuela, J.-M., Deininger, M., Fabarius, A., Kim, D. D. H., Machova Polakova, K., Radich, J. P., Hehlmann, R., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02048-y · Cited by 120
Self-citationJiang, Q., Li, Z., Qin, Y., Li, W., Xu, N., Liu, B., Zhang, Y., Meng, L., Zhu, H., Du, X., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01334-z · Cited by 102
Soverini, S., Bavaro, L., De Benedittis, C., Martelli, M., Iurlo, A., Orofino, N., Sica, S., Sorà, F., Lunghi, F., Ciceri, F., et al. (2020) · Blood · doi:10.1182/blood.2019002969 · Cited by 100
Self-citationÅgerstam, H., Hansen, N., von Palffy, S., Sandén, C., Reckzeh, K., Karlsson, C., Lilljebjörn, H., Landberg, N., Askmyr, M., Högberg, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679985 · Cited by 98
Opportunities and challenges in combination gene cancer therapy
Nastiuk, K. L., & Krolewski, J. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.005 · Cited by 85
“Finally, in the case of bcr-abl, second and third generation TKIs have not been entirely successful in treating resistant CML [57] but a combination of imatinib and a novel therapy directed against Stat3 has shown some success in pre-clinical studies [58].”
BackgroundJabbour, E., Oehler, V. G., Koller, P. B., Jamy, O., Lomaia, E., Hunter, A. M., Uspenskaya, O., Samarina, S., Mukherjee, S., Cortes, J. E., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2024.5157 · Cited by 33
Self-citationSoverini, S., Martelli, M., Bavaro, L., De Benedittis, C., Sica, S., Sorà, F., Iurlo, A., Bonifacio, M., Pregno, P., Galimberti, S., et al. (2021) · Leukemia · doi:10.1038/s41375-020-01098-w · Cited by 29
Self-citationSponseiler, I., Bandian, A., Pusic, P., & Lion, T. (2024) · American Journal of Hematology · doi:10.1002/ajh.27095 · Cited by 11
Novel Calcium-Binding Ablating Mutations Induce Constitutive RET Activity and Drive Tumorigenesis
(2022) · doi:10.1158/0008-5472.can-22-0834 · Cited by 6
Tabata, J., Nakaoku, T., Araki, M., Yoshino, R., Kohsaka, S., Otsuka, A., Ikegami, M., Ui, A., Kanno, S.-I., Miyoshi, K., et al. (2023) · doi:10.1158/0008-5472.c.6514040.v1
Metadata
- Authors
- Zabriskie, M. S., Eide, C. A., Tantravahi, S. K., Vellore, N. A., Estrada, J., Nicolini, F. E., Khoury, H. J., Larson, R. A., Konopleva, M., Cortes, J. E., Kantarjian, H., Jabbour, E. J., Kornblau, S. M., Lipton, J. H., Rea, D., Stenke, L., Barbany, G., Lange, T., Hernández-Boluda, J.-C., Ossenkoppele, G. J., Press, R. D., Chuah, C., Goldberg, S. L., Wetzler, M., Mahon, F.-X., Etienne, G., Baccarani, M., Soverini, S., Rosti, G., Rousselot, P., Friedman, R., Deininger, M., Reynolds, K. R., Heaton, W. L., Eiring, A. M., Pomicter, A. D., Khorashad, J. S., Kelley, T. W., Baron, R., Druker, B. J., Deininger, M. W., & O’Hare, T.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 26
- Issue
- 3
- Pages
- 428-442
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2140351909
- Cited by
- 363
- References
- 47
- FWCI
- 24.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.